<DOC>
	<DOCNO>NCT00814892</DOCNO>
	<brief_summary>RATIONALE : Vaccines make tumor cell dendritic cell may help body build effective immune response kill tumor cell . It yet know vaccine effective treating patient prostate cancer . PURPOSE : This phase II trial study well combination proven effective allogenic whole prostate carcinoma cell ( APCC ) vaccine co-administered ex vivo generate dendritic cell ( DCs ) ( DC-APCC ) extend time prostate cancer progression .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Non-Metastatic Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine proportion patient androgen-independent prostate cancer progression-free one year treatment DC-APCC . Secondary - Evaluate treatment toxicity . - Evaluate time prostate-cancer specific mortality . - Evaluate progression-free survival . - Evaluate time PSA progression , duration PSA-based response . - Evaluate quality life patient treat regimen . OUTLINE : Patients undergo standard leukapheresis harvest peripheral blood mononuclear cell dendritic cell vaccine preparation receive APCC vaccine autologous dendritic cell derive CD14-positive myeloid peripheral blood cell ID every 2 week first 2 treatment ( cycle 1 2 ) , every 4 week therafter 14 administration absence disease progression unacceptable toxicity . The first four patient observe four week follow third DC-APCC vaccination ass toxicity , enrollment patient continue toxicity relate event present . Patients undergo blood sample collection periodically translational study . Samples measure number immune parameter quantify T-cell dentritic cell population analysis surface marker molecule flow cytometry , T-cell proliferation assay , non-specific cytokine release , lysate-specific cytokine release , cytokine expression measure cytometric bead array qPCR . Patients complete quality-of-life questionnaire periodically . After completion study treatment , patient follow periodically 3 year . PROJECTED ACCRUAL : A total 35 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate Biochemically progressive disease define two serial PSA measurement obtain ≥ 1 week apart ongoing optimal androgendeprivation therapy ( e.g. , orchiectomy , luteinizing hormonereleasing hormone [ LHRH ] agonist , another equivalent hormonal agent ) Concurrent LHRH agonist highdose bicalutamide require ( unless patient undergone prior orchiectomy ) Has undergone prior standard primary therapy prostate cancer ( e.g. , radical prostatectomy , radiotherapy , equivalent initial treatment direct towards localize prostate cancer ) PSA 2.0100.0 ng/mL Serum testosterone &lt; 50 ng/dL ( unless undergo antiandrogen monotherapy ) No concurrent evidence radiological new clinically palpable metastatic cancer PATIENT CHARACTERISTICS : ECOG performance status 01 Life expectancy ≥ 12 week WBC ≥ 3,500/µL Platelet count ≥ 100,000/µL Hemoglobin ≥ 10.0 g/dL Creatinine ≤ 2.0 mg/dL Alkaline phosphatase ≤ 2.5 time upper limit normal ( ULN ) AST ≤ 2.5 time ULN Fertile patient must use effective contraception Willing provide blood sample research purpose Able complete questionnaire ( ) alone assistance Able undergo leukapheresis No known immunodeficiency No malignancy within past 5 year except basal cell squamous cell carcinoma skin treat local resection No concurrent serious illness No known history positive PPD skin test PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered prior therapy More 1 month since prior concurrent corticosteroid immunosuppressive agent Inhaled corticosteroid allow More 1 month since prior concurrent estrogen and/or ketoconazole More 3 month since prior concurrent investigational medicinal product More 4 week since prior concurrent secondary hormonal maneuver without peripheral antiandrogen ( e.g. , bicalutamide ) , PCSPES , herbal medicine use treat prostate cancer No prior prostate cancer vaccine No therapy prostate cancer ( e.g. , chemotherapy , immunotherapy , radiotherapy , new hormonal therapy ) 4 month completion study therapy No concurrent standard therapy potentially curative proven capable extend life expectancy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
</DOC>